PHARMACOECONOMIC ANALYSIS OF DIFFERENT METHODS FOR THE TREATMENT OF STEROID-REFRACTORY GRAFT-VERUS-HOST DISEASE: SINGLE-CENTER STUDY

Introduction. Steroid-refractory graft-versus-host disease (srGVHD) is one of the most severe and life-threatening complications of allogeneic hematopoietic stem cell transplantation. Currently, there is no standard treatment for this complication. In addition, there is no data on the pharmacoeconomics of various methods in the Russian Federation. The objective is to compare the effectiveness and cost of treatment of acute and chronic srGVHD, as well as the use of different approaches in therapy. Material and methods. We have conducted a pilot study in 12 srGVHD patients treated with ruxolitinib and in 24 patients of wellmatched historical control, who treated with etanercept for the acute srGVHD and with extracorporeal photopheresis for chronic srGVHD. Results. The 6-month therapy of acute GVHD was associated with significantly higher cost than therapy of chronic GVHD (4.138±2.672 vs 1.862±1.122 thd. rub., р=0.004). The major factors driving up the costs were bacterial infections (р=0.022), opportunistic viral infections (р<0.001), severity of GVHD at the start of a therapy (р=0.013) and GI involvement (р=0.006). There was no difference in 1-year failure-free survival in acute (50 % vs 67 %, р=0.9) and chronic GVHD (87.5 % vs 87.5 %, р=1.0) between ruxolitinib and the control group, although the overall response was faster in ruxolitinib group (100 % vs 71 %, р=0.035, when assessed at 28 days in acute and 12 weeks in chronic srGVHD). The mean 6-month overall costs in the ruxolitinib were higher compared to the control group (1534 thd. rub. higher for acute and 541 thd. rub. higher for chronic GVHD), however this might be attributed to higher number of previous lines in the ruxolitinib group. Conclusions. It is revealed that the treatment of acute srGVHD requires significantly higher economic costs than chronic srGVHD. The power of this study does not allow to draw conclusions regarding the efficacy of different methods. Further studies are required to determine the optimal therapy of srGVHD.

1. Savchenko V.G.., Lubimova L.S., Parovichnikova E.N. et al. Transplantations of allogenic and autologous hemopoietic stem cells in acute leukemia (results of 20-year experience. Ter Arkh. 2007;79(7):30-5.

2. Stephen J. Forman, Robert S. Negrin, Joseph H. Antin, Frederick R. Appelbaum. Thomas’ Hematopoietic Cell Transplantation, Fifth Edition. 2016. Wiley, NY, USA.

3. Maschan M, Shelikhova L, Ilushina M et al. TCR-alpha/ beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant. 2016 May;51(5):668-74.

4. Moiseev IS, Pirogova OV, Alyanski AL et al. Graftversus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. Biol Blood Marrow Transplant. 2016 Jun;22(6):1037-42.

5. Saliba RM, Couriel DR, Giralt S et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. 2012 Jan;47(1):125-31.

6. Koc S, Leisenring W, Flowers ME et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002 Jul 1;100(1):48-51.

7. Martin PJ, Rizzo JD, Wingard JR et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63.

8. Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012 Aug 23;120(8):1545-51.

9. Passweg JR, Baldomero H, Bader P et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually. Bone Marrow Transplant. 2016 Jun;51(6):786-92.

10. Ruutu T, Gratwohl A, de Witte T et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014 Feb;49(2):168-73.

11. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828.

12. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956.

13. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010 Jul 1;115(26):5412-7.

14. Lee SJ, Wolff D, Kitko C et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015 Jun;21(6):984-99.

15. Prikladnaya pharmacologia. Under edition of V.I. Petrov. 2007; GOETAR-Media, p 14-25., Moscow.

16. Metodicheskie recomendatcii po otcenke sravnitelnoi klinicheskoi effectivnosti I bezopasnosti lekarstvennogo preparata. / Omelyanovskii VV, Avksent’ieva MV, Sura MV, Hachataryan GR, Fedyaeva VK. 2016; Moscow.

17. Hang Lee. Foundations of applied statistical methods. Springer, Boston, MA, USA, 2014.

18. Bil of the government No 28.08.2014 N 871 (ed. from 12.06.2017) «Ob utvergdenii pravil formirovaniya perechnei lekarstvennih preparatov dlya medicinskogo premineniya I minimalnogo assortimenta lekarstvennih preparatov, neobhodimih dlya okazaniya pervoi pomoschi».

19. Griffiths RI, Bass EB, Powe NR et al. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant. 1993 Jul;12(1):43-8.

20. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol 2000;18(1):64-71.

21. Khera N, Emmert A, Storer BE et al. Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens. Oncologist. 2014 Jun;19(6):639-44.

22. Zeiser R, Burchert A, Lengerke C et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015 Oct;29(10):2062-8.

23. Malagola M, Cancelli V, Skert C et al. Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo. Transplantation. 2016 Dec;100(12):e147- e155.

24. Clinicaltrials.gov, as of 27.12.2017